Valuation
- Market cap
- 29,579,000
- Revenue TTM
- $0
- Net income TTM
- $-26,310,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 137,200
- Avg volume
- 316,000
- Day's range
- $3.39 – $3.91
- Shares out
- 8,700,000
- Stochastic %K
- 1%
- Beta
- 1.21
- Analysts
- Strong Buy
- Price target
- $40.00
Company profile
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator...
Show more
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate the
clinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. The company is headquartered in West Vancouver, Canada.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 604 921 1810
- Website
- https://briacell.com
- Address
- Bellevue Centre, Suite 300 235 -15th Street, West Vancouver, Canada
Latest news
No headlines yet.
Stocktwits
JediGreen
Oct 18, 12:08 AM
$BCTX I’ll be re-entering the market soon. Will have 10k soon to play with as I wait and see how my 115k turns out in this ben stuck in this for a year but have a feeling this company could be bought out and we all will bank. But as we wait. Let’s see if I can take 10k and turn it into 100k in like 6 months. 🙂 Ben to long since I touched my keyboard and mouse.
0 replies
Biotechlineup
Oct 17, 2:44 PM
$BCTX Just a casual remark. Doesn’t this just amaze everyone??
"We're getting extremely interesting results already with our first patient who came in, had a lung metastasis, had failed several prior therapy attempts and with four cell inoculations every two weeks, the lung metastasis completely cleared..."
0 replies
Biotechlineup
Oct 17, 2:10 PM
$BCTX Just another speculation, in the worst case scenario where they miss the .7 HR in the combined arm .
Think about this the TNBC patients subgroup in phase 2 had a .54 HR ! With minimal side effects. So drastically almost doubles life expectancy with a high quality of life.
Another speculation even in that case the FDA carves out an approval for the sub group.
1 replies
Biotechlineup
Oct 17, 1:57 PM
$BCTX This is why biotech investing is a lot of speculation. The key word was “Hockey Stick” few weeks ago they implied enrollment had accelerated rapidly from the May/26 180 patients because it had gone hockey stick. When asked about an update , management said we will wait until full enrollment. Boom ! They confirmed it’s done. Now they were very confident on a year end read out. How can that be?? Many of us have run multi variable Monte Carlo’s . Only way is if the TNBC group is overly represented . Management is not completely blinded, they can infer from other parameters the mix. Thats my speculation.
0 replies
JediGreen
Oct 17, 6:17 AM
$BCTX https://www.investors.com/news/technology/biotech-stocks-2026-mergers-acquisitions-2027-forecast/
0 replies
JediGreen
Oct 17, 4:19 AM
$BCTX This might be a really good sign. I’d consider this shaking the tree 🌳. My opinion someone is trying to get people out to cover or load up or could even be market makers.
0 replies
Biotechlineup
Oct 17, 3:29 AM
$BCTX So according to management using present tense language with 177 already enrolled in each arm , the 354 total did truly Hockey stick as they previously stated. I think that went over the analysts head. This is now being driven by the control arm. Very likely management has a good feel for the expectations on the previous year end expectations. Since they said cash run through 2nd qtr and expenses drop rapidly in the observable stage of a trial , all we have to do is wait.
1 replies
